Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy - PubMed
3 hours ago
- #naturally-occurring antibodies
- #ATTR cardiomyopathy
- #transthyretin stabilizer
- Naturally-occurring antibodies targeting transthyretin (nAbsTTR) are present in humans from birth, binding both native and amyloid TTR with high affinity.
- In ATTR cardiomyopathy (ATTR-CM), nAbsTTR levels are altered: IgG subtype increases while IgM decreases compared to controls.
- Transthyretin stabilizer therapy significantly increases nAbsTTR levels by 22% in ATTR-CM patients, and these antibodies inhibit TTR fibril formation in vitro.
- This study suggests an unrecognized immune mechanism in ATTR-CM pathogenesis and treatment, with implications for therapeutic strategies.